15:I[1530,["375","static/chunks/375-20d7c80f693d3a70.js","927","static/chunks/927-ab49aa98b43490bd.js","241","static/chunks/241-bdf55b662a8e1e6c.js","418","static/chunks/418-9884ed026ebd3257.js","530","static/chunks/530-467d591143ad18d2.js","277","static/chunks/app/news/%5B...slug%5D/page-28088fd48e0a1795.js"],"Post"] d:[["$","meta","0",{"name":"viewport","content":"width=device-width, initial-scale=1"}],["$","meta","1",{"charSet":"utf-8"}],["$","title","2",{"children":" Corline Biomedical årsredovisning för 2020 | Corline biomedical"}],["$","link","3",{"rel":"manifest","href":"/manifest.webmanifest","crossOrigin":"use-credentials"}],["$","link","4",{"rel":"icon","href":"/favicon.ico","type":"image/x-icon","sizes":"48x48"}],["$","link","5",{"rel":"icon","href":"/icon.svg?8f72dc22dac66db2","type":"image/svg+xml","sizes":"any"}],["$","link","6",{"rel":"apple-touch-icon","href":"/apple-icon.png?020805df65bebd84","type":"image/png","sizes":"180x180"}],["$","meta","7",{"name":"next-size-adjust"}]] 7:null 16:T76f,

Corline Biomedical AB (”Corline”) publicerar idag sin årsredovisning för bokföringsåret 2020, vilken tillgängliggörs via bolagets hemsida www.corline.se.

För mer information om Corline, vänligen kontakta
Henrik Nittmar, VD
Telefon: +46 (0)18 71 30 90
E-post: henrik.nittmar@corline.se

Certified Adviser
Redeye AB, Mäster Samuelsgatan 42, 103 87 Stockholm. Telefon: +46 (0)8-121 576 90. E-post: certifiedadviser@redeye.se.

Corline Biomedical AB, noterat på First North Growth Market (CLBIO), arbetar med den kroppsegna substansen heparin och har utvecklat en portfölj med läkemedelskandidater för användning i anslutning till organ- och cellt

Corline Biomedical årsredovisning för 2020

Relaterade Nyheter